NOVAVAX INC
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.12B | $682.2M | $983.7M | $1.98B | $1.15B | $475.6M | $18.7M |
| Cost of Revenue | — | $73.0M | $202.7M | $343.8M | $902.6M | $0 | $0 | — |
| Gross Profit | — | $1.05B | $479.4M | $639.9M | $1.08B | $1.15B | $475.6M | — |
| Gross Margin | — | 93.5% | 70.3% | 65.1% | 54.5% | 100.0% | 100.0% | — |
| Operating Expenses | ||||||||
| Research & Development | — | $342.3M | $391.2M | $737.5M | $1.24B | $2.53B | $747.0M | $113.8M |
| SG&A Expense | — | $157.5M | $337.2M | $468.9M | $488.7M | $298.4M | $145.3M | $34.4M |
| Operating Income | — | $452.8M | $-248.9M | $-566.5M | $-644.7M | $-1.69B | $-416.7M | $-120.6M |
| Operating Margin | — | 40.3% | -36.5% | -57.6% | -32.5% | -147.1% | -87.6% | -646.1% |
| Interest Expense | — | $11.5M | $10.4M | $14.4M | $19.9M | $21.1M | $15.1M | $13.6M |
| Pretax Income | — | $442.2M | $-176.6M | $-543.0M | $-653.6M | $-1.71B | $-418.3M | $-132.7M |
| Income Tax Expense | — | $1.9M | $10.9M | $2.0M | $4.3M | $29.2M | $0 | $0 |
| Net Income | — | $440.3M | $-187.5M | $-545.1M | $-657.9M | $-1.74B | $-418.3M | $-132.7M |
| Net Margin | — | 39.2% | -27.5% | -55.4% | -33.2% | -152.1% | -87.9% | -711.0% |
| EPS (Basic) | — | $2.72 | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.27 | $-2.76 |
| EPS (Diluted) | — | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.27 | $-2.76 |
| Shares Outstanding (Basic) | 162.9M | 162.0M | 152.2M | 100.8M | 78.2M | 74.4M | 57.6M | 48.2M |
| Shares Outstanding (Diluted) | 162.9M | 173.1M | 152.2M | 100.8M | 78.2M | 74.4M | 57.6M | 48.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |